Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Sanofi, with a price target of €103.00. The company’s shares closed yesterday at $96.65. Quigley covers the ...

Sabic to close UK cracker, plastics recycler Novoloop raises funds, Kymera strikes molecular glue deal, and more ...

UBS analyst Colin White maintained a Buy rating on Sanofi (SNYNF – Research Report) today. The company’s shares closed yesterday at $94.99. Don’t Miss TipRanks’ Half-Year ...

The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” the analysts said, citing its potential to rival blockbuster drugs like ...

The firm noted that Sanofi’s decision to discontinue the development of KT-474 and focus on KT-485 could impact the timelines in certain markets. Brookline Capital Markets, on the other hand, lowered ...

Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering.